T2109

SD-208 (ALK5 Inhibitor V), a selective TGF-βRI (ALK5) inhibitor (IC50: 48 nM), is >100-fold selectivity over TGF-βRII.

HSV-1-IN-3 (Compound A50) is an inhibitor of HSV, exhibiting strong antiviral efficacy against both acyclovir-sensitive and acyclovir-resistant strains of HSV.

5α-Androstan-3α-ol is a γ-aminobutyric acid (GABA) receptor agonist. It inhibits the transcriptional activity of the orphan nuclear receptor CAR (constitutive androstane receptor). By binding to CAR and promoting its dissociation from coactivator proteins, 5α-Androstan-3α-ol negatively regulates CAR's activity. This compound is useful for studying hormone metabolism and drug detoxification mechanisms mediated by nuclear receptors.

STAT6-IN-7 (Compound 178) is a STAT6 inhibitor with an IC50 of 0.28 μM for inhibiting the binding of human STAT6/pIL-4Rα. It is utilized in research related to inflammation and allergic diseases.

Neuroprotective agent 12 is an orally active compound capable of crossing the blood-brain barrier, offering significant neuroprotective properties. It exhibits robust antioxidant and anti-inflammatory effects, markedly inhibiting cell death induced by glutamate and acrolein. This agent reduces the expression of PDE4B while elevating levels of HO-1, p-CREB, and BDNF. In a traumatic brain injury (TBI) mouse model, Neuroprotective agent 12 demonstrates potent neuroprotection and holds potential for research into TBI and other central nervous system disorders.

Benzotriazole BT-D10 is the deuterated form of UV-234.

3,3'-Dihydroxybenzidine is a bioactive chemical.

Ergothioneinesulfonate, a sulfonic acid derivative of ergothioneine, exhibits antioxidant properties. It is converted into a stable sulfonate form through redox reactions. This compound can be utilized in research focused on the mechanisms underlying inflammation and oxidative stress-related diseases.

AMPA-IN-2 is an orally effective AMPA inhibitor capable of crossing the blood-brain barrier. By suppressing intrinsic neuronal excitability and inhibiting glutamatergic transmission excitability, AMPA-IN-2 alleviates seizures. In the pentylenetetrazol (PTZ) model, it demonstrates anticonvulsant effects, positioning it as a promising candidate with high broad-spectrum antiepileptic potential.

TRPV1 agonist-1 (Compound 13) is a non-irritant TRPV1 agonist that is effective when administered orally. It shows EC50 values of 4.5 nM for humans and 0.57 nM for rats. TRPV1 agonist-1 has the capability to improve swallowing function in rats and is applicable for research on dysphagia.

HDAC6-IN-59 (Compound 38k) is a highly selective inhibitor of histone deacetylase 6 (HDAC6), with an IC50 of 3.12 nM and a 352-fold selectivity over HDAC1. It holds potential for research in esophageal cancer.

3-Bromocarbazole-D7 is the deuterium-labeled version of 3-Bromocarbazole (TYD-00527). This compound serves as a biochemical reagent and can be utilized as a biomaterial or organic compound in research related to life sciences.

MTP3 ligand-1 is the MTP3 ligand component of PROTAC MTP3 degrade-1. PROTAC MTP3 degrade-1 functions as a PROTAC degrader for MYC.

WZH-15-125 is a potent ALK inhibitor capable of overcoming resistance, particularly with complex ALK mutations. It exhibits an IC50 of 101.7 nM against the highly recalcitrant Lorlatinib-resistant G1202R/L1196M mutation. Additionally, WZH-15-125 can serve as a PROTAC target protein ligand for synthesizing PROTACWZH-17-002. This compound is applicable in non-small cell lung cancer research.

AH001 is an orally active compound that binds to a concealed pocket near GDP within RhoA, exhibiting a binding affinity of 73.16 nM. By interacting with GDP, AH001 stabilizes the interaction between RhoA and its endogenous inhibitor, RhoGDIα. This compound reduces nuclear translocation of downstream MRTFA and downregulates fibrosis/hypertrophy-related proteins. AH001 alleviates myocardial remodeling in various heart failure animal models and 3D cardiac tissue models. Its cardioprotective effects are mediated through the RhoA-RhoGDIα axis, effectively inhibiting downstream RhoA activation signals.

SARM1-IN-6 (Compound 17a) is a brain-penetrant orthosteric inhibitor of SARM1. It exhibits an IC50 of 14 nM against NAM and 74 nM against HEK cells.

(S,R,S)-AHPC-amide-PEG5-C2-azide (VH032-CO-(CH2)2-(O-CH2-CH2)5-azide) is a PROTAC linker. This compound is utilized in the synthesis of PROTAC molecules.

AR493 is an autophagy activator that targets AMPK (adenosine monophosphate-activated protein kinase). It modulates pathways related to cellular energy sensing and enhances autophagy levels. AR493 holds potential for use in age-related diseases (such as diabetes and neurodegenerative diseases) and in the research of autophagy regulation.

HC2210 exhibits antibacterial effects against Mycobacterium abscessus (Mab) with an EC50 of 0.72 µM. It modulates the expression of Mab genes associated with oxidative stress and lipid metabolism. HC2210 is applicable for studies on Mab infections.

4-Hydroxybenzylamine (4-HOBA) is a less reactive isomer of 2-HOBA as well as related compounds in a mouse model of hypertension.

5-HT2A receptor agonist-10 (Compound (R)-I-121.HCl) acts as a 5-HT2A receptor agonist with IC50 values of 2192.39 nM for h5-HT2A and 33.57 nM for h5-HT1A. It is applicable in research related to psychiatric disorders, mental illnesses, and central nervous system diseases.

KARI 201 hydrochloride is a selective, brain-penetrant, competitive inhibitor of acid sphingomyelinase (ASM) with an IC50 of 338.3 nM. It also acts as an agonist for the growth hormone-releasing peptide receptor (ghrelin receptor). Additionally, KARI 201 hydrochloride can enhance the neuropathological features of Alzheimer's disease.

Keap1-IN-2 (Compound 164) is an inhibitor of KEAP1 with an IC50 of 2 nM. It indirectly activates Nrf2 by blocking KEAP1, thereby enhancing cellular antioxidant capacity. By preventing KEAP1-mediated degradation of Nrf2, Keap1-IN-2 promotes the accumulation and nuclear translocation of Nrf2. This compound is used in research on diseases related to oxidative stress, such as inflammatory bowel disease, Crohn's disease, and ulcerative colitis, which are immune-related conditions.

1,2,3,4,5-Pentabromo-6-ethylbenzene-13C6 is the 13C-labeled version of 1,2,3,4,5-Pentabromo-6-ethylbenzene.